TGFB1 and neoplasm: Promising agents with bone-anabolic actions that do not directly inhibit tumor proliferation include TGFβ inhibitors and neutralizing antibodies against the WNT inhibitors DKK1 and sclerostin (which are negative regulators of bone formation).